40. 高安動脈炎 Takayasu arteritis Clinical trials / Disease details


臨床試験数 : 24 薬物数 : 40 - (DrugBank : 18) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 110

  
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05151848
(ClinicalTrials.gov)
January 5, 20226/11/2021Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu ArteritisAn Open-label,Randomized, Controlled, Multicenter Study of Adalimumab and Tofacitinib in the Treatment of Active Takayasu ArteritisTakayasu ArteritisDrug: Adalimumab Injection;Drug: Tofacitinib 5 MGChinese SLE Treatment And Research GroupNULLRecruiting18 Years65 YearsAll100Phase 4China
2JPRN-jRCT2061210007
13/10/202128/05/2021A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu Arteritis Takayasu ArteritisUstekinumab
Participants will receive IV infusion and SC injection of ustekinumab.

Placebo
Participants will receive IV infusion and SC injection of matching placebo.

Glucorticoid Taper Regimen
Glucocorticoid will be administered orally.
Nishikawa KazukoNULLRecruiting>= 18age old<= 75age oldBoth50Phase 3Japan
3NCT04882072
(ClinicalTrials.gov)
September 15, 202110/5/2021A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Participants With Takayasu ArteritisTakayasu ArteritisDrug: Ustekinumab;Other: Placebo;Drug: Glucorticoid Taper RegimenJanssen Pharmaceutical K.K.NULLActive, not recruiting15 Years75 YearsAll14Phase 3Japan
4NCT05168475
(ClinicalTrials.gov)
July 14, 20219/12/2021Biologics in Refractory VasculitisBiologics in Refractory Vasculitis (BIOVAS): A Pragmatic, Randomised, Double-blind, Placebo-controlled, Modified-crossover Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis in Adults and ChildrenGiant Cell Arteritis;Takayasu Arteritis;Cogan Syndrome;Relapsing Polychondritis;Cryoglobulinemic Vasculitis;IgA Vasculitis;Polyarteritis Nodosa;Cutaneous Polyarteritis Nodosa;Primary Angiitis of Central Nervous SystemBiological: Rituximab;Biological: Infliximab;Biological: TocilizumabCambridge University Hospitals NHS Foundation TrustNULLRecruiting5 YearsN/AAll140Phase 2United Kingdom
5NCT04564001
(ClinicalTrials.gov)
September 202021/9/2020Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu ArteritisMulticentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu ArteritisTakayasu ArteritisDrug: Infliximab;Drug: TocilizumabAssistance Publique - Hôpitaux de ParisNULLNot yet recruiting18 YearsN/AAll50Phase 2NULL
6NCT04300686
(ClinicalTrials.gov)
March 1, 20205/3/2020A Pilot Study in Severe Patients With Takayasu Arteritis.A Pilot Study in the Treatment of Severe Patients With Takayasu Arteritis With Tocilizumab and Adalimumab, Based on ECTA CohortTakayasu Arteritis;Tocilizumab;Adalimumab;TreatmentBiological: Tocilizumab;Biological: AdalimumabShanghai Zhongshan HospitalNULLRecruiting14 Years100 YearsAll40Phase 4China
7NCT04299971
(ClinicalTrials.gov)
March 1, 20205/3/2020Efficiency of Methotrexate and Tofacitinib in Mild and Moderate PatientsRandomized Open-label Study in Mild and Moderate Patients With Takayasu Arteritis Between Methotrexate and Tofacitinib Based on the ECTA Cohort.Takayasu Arteritis;Methotrexate;Inhibition;TreatmentDrug: Methotrexate Tablets;Drug: Tofacitinib tabletShanghai Zhongshan HospitalNULLRecruiting14 Years100 YearsAll130Phase 4China
8NCT04161898
(ClinicalTrials.gov)
February 4, 202012/11/2019A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)Takayasu Arteritis (TAK)Drug: Upadacitinib;Drug: Placebo for Upadacitinib;Drug: PrednisoloneAbbVieNULLRecruiting15 YearsN/AAll56Phase 3Argentina;Brazil;China;Japan;Korea, Republic of;Turkey
9EUCTR2018-003753-13-FR
(EUCTR)
19/03/201913/12/2018INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritisMulticentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]Trade Name: RoActemra 20mg/ml
Product Name: Tocilizumab
INN or Proposed INN: Tocilizumab
Other descriptive name: TOCILIZUMAB
Product Name: Infliximab
INN or Proposed INN: INFLIXIMAB
ASSISTANCE PUBLIQUE - HOPITAUX DE PARISNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 3France
10NCT03482479
(ClinicalTrials.gov)
February 4, 201922/3/2018Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisLow Dose Naltrexone to Improve Physical Health in Patients With VasculitisEosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu ArteritisDrug: Naltrexone Hydrochloride;Other: Placebo ComparatorUniversity of PennsylvaniaNULLRecruiting18 YearsN/AAll36Phase 2United States
11NCT03550781
(ClinicalTrials.gov)
June 1, 20185/5/2018Anti-inflammatory Treatment for Inactive Takayasu ArteritisDoes Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment?Takayasu Arteritis;Anti-Inflammatory AgentsDrug: Prednisone, cyclophosphamideChinese Academy of Medical Sciences, Fuwai HospitalNULLNot yet recruiting10 Years40 YearsAll40Phase 2/Phase 3NULL
12NCT03430388
(ClinicalTrials.gov)
January 31, 201830/1/2018Yellow Fever Vaccine in Patients With Rheumatic DiseasesEvaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk AreaSystemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile DermatomyositisBiological: Yellow Fever vaccine (17D)University of Sao Paulo General HospitalNULLCompleted2 Years60 YearsAll600N/ABrazil
13NCT03096275
(ClinicalTrials.gov)
March 16, 201713/3/2017Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisComparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's ArteritisTakayasu ArteritisDrug: MMF;Drug: CYC;Drug: Glucocorticoids;Drug: MTX;Drug: AZAChinese SLE Treatment And Research GroupPeking Union Medical College HospitalActive, not recruiting18 YearsN/AAll138Phase 3China
14NCT03192878
(ClinicalTrials.gov)
March 1, 20179/5/2017Infliximab Biosimilar in Takayasu's ArteritisA Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive TreatmentsTakayasu ArteritisDrug: InfliximabOspedale San RaffaeleNULLRecruiting18 YearsN/AAll30N/AItaly
15JPRN-UMIN000025940
2017/02/0707/02/2017Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu ArteritisClinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu Arteritis - TOCIlizumab treatment for TAKayasu arteritis (TOCI-TAK) Takayasu arteritisIntravenous administration of
tocilizumab (8mg/kg/month) for up to 12 months
Osaka UniversityNational Cerebral and Cardiovascular CenterComplete: follow-up continuing16years-old60years-oldMale and Female2Not selectedJapan
16NCT03199183
(ClinicalTrials.gov)
January 1, 201723/6/2017Registration Study of Takayasu's Arteritis in ChinaRegistration Study of Takayasu's Arteritis in ChinaTakayasu ArteritisRadiation: PET-CT;Other: laboratory biomarker analysis;Genetic: genetic sequencingChina National Center for Cardiovascular DiseasesNULLRecruitingN/AN/AAll1067China
17NCT03893136
(ClinicalTrials.gov)
November 1, 201612/3/2019The Registry Study of Takayasu Arteritis in East ChinaThe Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study)Takayasu Arteritis;Mechanisms, Defense;Pregnancy Related;Treatment Refusal;OutcomeBiological: Tocilizumab;Drug: LeflunomideShanghai Zhongshan HospitalNULLRecruiting18 Years65 YearsAll1000China
18NCT02457585
(ClinicalTrials.gov)
March 201518/5/2015Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu ArteritisAnti-tumor Necrosis Factor Therapy Effect on Takayasu ArteritisTakayasu's ArteritisDrug: remicade (anti tumor necrosis factor inhibitor)Seoul National University HospitalNULLRecruiting18 YearsN/AAll11Phase 2Korea, Republic of
19JPRN-JapicCTI-142616
02/10/201423/07/2014Phase III Study of MRA-SC in Patients with Takayasu ArteritisA Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu Arteritis Takayasu ArteritisIntervention name : tocilizumab (MRA-SC)
INN of the intervention : tocilizumab
Dosage And administration of the intervention : 162mg/W, SC
Control intervention name : Placebo
INN of the control intervention : -
Dosage And administration of the control intervention : Placebo/W, SC
Chugai Pharmaceutical Co., Ltd.NULLcomplete12BOTH34Phase 3Japan
20JPRN-UMIN000025943
2014/08/0707/02/2017Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisLong-term Safety of treatment with tocilizumab in the refractory patients with Takayasu Arteritis - Long-term ACTemra Investigation for remissION introduction in TAKayasu Arteritits (LACTION-TAK) Takayasu arteritisIntravenous administration of
tocilizumab (8mg/kg/month) will be performed until December 31st, 2017.
Osaka UnversityNational Cerebral and Cardiovascular CenterComplete: follow-up continuing16years-old60years-oldMale and Female9Not selectedJapan
21NCT02101333
(ClinicalTrials.gov)
June 10, 201417/2/2014Efficacy and Tolerance of Tocilizumab In Takayasu ArteritisEfficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter StudyTAKAYASU ARTERITISDrug: TocilizumabAssistance Publique - Hôpitaux de ParisChugai PharmaceuticalCompleted18 Years77 YearsAll18Phase 3France
22JPRN-UMIN000008812
2012/10/0101/10/2012Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR) - Treatment of LVV and PMR by tocilizumab mono-therapy Rheumatoid arthritistocilizumab monotherapyDepartment of Rheumatology & Clinical ImmunologySaitama Medical Center, Saitama Medical UniversitityNULLComplete: follow-up complete16years-old80years-oldMale and Female40Not selectedJapan
23JPRN-UMIN000007845
2012/05/0101/05/2012Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisEfficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu Arteritis - ACTemra Investigation for remissiON introduction in Takayasu Arteritits (ACTION-TA) Takayasu arteritisIntravenous administration of tocilizumab (8mg/kg/month) for 24 monthsDepartment of Cardiovascular Medicine Graduate School of Medicine Osaka UniversityNULLComplete: follow-up continuing16years-old60years-oldMale and Female15Not selectedJapan
24NCT00006055
(ClinicalTrials.gov)
March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States